Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...

Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful ...

Key Points GAAP EPS loss of $9.09 was narrower than the expected $9.24 per share for Q2 2025, a minor outperformance. Research and development expenses (GAAP) rose 29.2% to $2.2 million, reflecting ...

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies ...

Discover PDS Biotechnology's Q2 2025 progress on groundbreaking cancer trials, including VERSATILE-003. Explore durable outcomes and market growth potential.